Using Data to Drive Antimicrobial Stewardship in Post-Acute and Long-Term Care Facilities


Dheeraj Mahajan, MD, MBA, MPH, FACP

Muhammad Salman Ashraf, MBBS

Elizabeth Frentzel, MPH

Special Thanks !!

Learning Objectives





DEFINITION

"optimize the treatment of infections while reducing the adverse events associated with antibiotic use"

DATA POINTS



70% of NH residents **receive** one or more courses of antibiotics in a year



40%-75% of antibiotics prescribed in NH may be **unnecessary or inappropriate**



Cost of antibiotic use in NHs is \$ 38 to 137 million per year



Residents with higher antibiotic use are at **24 % higher** risk of antibiotic related **harm**



20 % of providers prescribe 80 % of antibiotics



40-75% of antibiotics in NH are prescribed incorrectly



50 % of antibiotics in NH are prescribed for **longer duration than necessary**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Parts 405, 431, 447, 482, 483, 485, 488, and 489


[CMS-3260-F]


RIN 0938-AR61

Medicare and Medicaid Programs; Reform of Requirements for Long-Term Care Facilities

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Final rule.





Calls for Action


White House call <u>for combating antibiotic</u> <u>resistant bacteria</u> (2014)

CDC's Core Elements of Antibiotic Stewardship for Nursing Homes (2015)

CMS regulations on LTC antimicrobial stewardship (2016)

Joint Commission's 2017 standard on antimicrobial stewardship

Establishing ASP in Nursing Home: the CDC Core Elements



Summary of Core Elements for Antibiotic Stewardship in Nursing Homes



Leadership commitment

Demonstrate support and commitment to safe and appropriate antibiotic use in your facility



Accountability

Identify physician, nursing and pharmacy leads responsible for promoting and overseeing antibiotic stewardship activities in your facility



Drug expertise

Establish access to consultant pharmacists or other individuals with experience or training in antibiotic stewardship for your facility



Action

Implement at least one policy or practice to improve antibiotic use



Tracking

Monitor at least one process measure of antibiotic use and at least one outcome from antibiotic use in your facility



Reporting

Provide regular feedback on antibiotic use and resistance to prescribing clinicians, nursing staff and other relevant staff



Education

Provide resources to clinicians, nursing staff, residents and families about antibiotic resistance and opportunities for improving antibiotic use

Obtain Leadership Statement of Support



Written statement of support for antimicrobial stewardship program (ASP)



Outline duties of the ASP team members



Communicate expectations with the nursing staff and prescribing providers



Create culture that promote appropriate antibiotic use

TRACHILY LUGUE

FROM: [Executive Director, Medical Director, Director of Nursing, etc.]

DATE: [Date]

RE: Antimicrobial Stewardship Program

Antibiotics are among the most commonly prescribed medications within long-term care facilities. However, misuse of antibiotics can lead to undesirable outcomes including emergence of multidrug resistant pathogens, development of *Clostridium difficile* infections, adverse drug reactions, increased mortality, and higher costs.

As part of the continuing commitment to provide high quality care to all our residents, the leadership team of [facility name] has created an Antibiotic Stewardship Program (ASP). This program will promote appropriate use of antibiotics in our facility. The overall goal of ASP is to prevent undesirable outcomes related to antibiotic misuse by optimizing the selection of drug, dose, route, and duration of therapy. Antibiotic use protocols and systems to monitor antibiotic use will be implemented to achieve ASP goals.

The ASP will be a part of the facility's Infection Prevention and Control Program. Infection preventionist will play a central role and the key leaders accountable for the program include [Medical Director, Director of Nursing, Consultant Pharmacist, etc.]. This multidisciplinary team will regularly review appropriateness of antibiotic courses and make recommendations for adjustment in practice where necessary, establish new or revise existing protocols relevant to appropriate antibiotic prescribing, monitor and report patterns of antibiotic use and resistance; and provide education on responsible use of antibiotics.

The success of this initiative requires the full participation and support of those who prescribe, prepare, administer, and receive antimicrobial therapy. The facility will provide adequate staffing and resources to support the functions and goals of the ASP. ASP team will engage prescribing providers, staff, residents, and residents' families to ensure that antibiotic use protocols can be implemented smoothly. Facility leadership is confident that with the help of frontline staff, support of prescribing providers, understanding of resident and families, and guidance of ASP team, we will improve quality of care and minimize untoward consequences of antibiotic therapy.

Leadership Support Statement

https://asap.nebraskamed.com



Establish Accountability

Empower leaders of the program

- Medical Director
- Director of Nursing
- Consultant Pharmacist

Provide dedicated time for ASP activities to:

- Program leaders
- Infection Preventionists (who will support day to day activities of ASP)
- Infection Advisory Committee of AMDA has recommended Infection Preventionists should get 10 hours/week dedicated towards ASP activities

Partner With Local Experts


or


Develop Expertise Within The Facility

Establish access to individuals with antibiotic expertise to implement antibiotic stewardship activities

Examples of experts include:

- Consultant pharmacists who have received specialized infectious diseases or antibiotic stewardship training
 - Many Consultant Pharmacists are being trained by their companies on Antimicrobial Stewardship concepts and activities
 - Training is also being made available to consultant pharmacists by national societies.
- Antibiotic stewardship program leads at the hospitals within your referral network.
- Develop relationships with infectious disease consultants in your community
- Medical Directors and Lead Physicians can also take courses that can help them prepare for ASP activities including CDC/SHEA/AMDA course.





Impact of Partnership with ID Specialists

- o 30% decrease in total antibiotic use
- o 64% decline in tetracyclines use
- o 61% decline in clindamycin use
- o 38% decline in fluroquinolones & sulfamethoxazole/trimethoprim
- 28% decline in beta lactam/ beta lactamase inhibitor use
- Rate of positive *C. difficile* tests at LTCF also declined while rate were the same in the hospital

JAMDA 18 (2017) 913-920

Develop Antibiotic Stewardship Policy

Outline the goals of the Antibiotic Stewardship program, structure and procedures of the antimicrobial stewardship committee along with responsibilities of its members



JAMDA

journal homepage: www.jamda.com



Special Article

Template for an Antibiotic Stewardship Policy for Post-Acute and Long-Term Care Settings



Robin L.P. Jump MD, PhD a,b,*, Swati Gaur MD, MBA, CMD Morgan J. Katz MD d, Christopher J. Crnich MD, PhD e,f, Ghinwa Dumyati MD Muhammad S. Ashraf MBBS h, Elizabeth Frentzel MPH , Steven J. Schweon RN, MPH, MSN, CIC, HEM , Philip Sloane MD, MPH , David Nace MD, MPH, CMD on behalf of the Infection Advisory Committee for AMDA—The Society of Post-Acute and Long-Term Care Medicine

[Facility Logo]

SUBJECT: Antimicrobial Stewardship Program

POLICY NO.: [Policy number]

EFFECTIVE DATE: [Policy effective date]

LAST REVISION DATE: [Date of last policy revision]

RELEVANT REGULATION: CFR § 483.80(a)(1)-(4)

APPROVED BY: [Approving individual or committee]

Policy Statement:

The goal of the Antimicrobial Stewardship Program (ASP) is to promote the appropriate use of antimicrobials in order to maximize treatment outcome and minimize unintended consequences of antimicrobial therapy. The ASP aims to improve antibiotic prescribing practices through the development and implementation of antibiotic use protocols and a system to monitor antibiotic use.

Structure:

The Antimicrobial Stewardship Committee has been established to provide support and oversee activities of the ASP. This committee and the ASP will be part of the Infection Prevention and Control Program (IPCP). The IPCP will directly report all ASP-related activities and outcomes to the Quality Assurance and Performance Improvement (QAPI) Committee. QAPI Committee will in turn report all ASP activities and outcomes to nursing staff, prescribing clinicians, and other relevant staff.

Procedure:


- Membership of the Antimicrobial Stewardship Committee
 - a. Medical Director (required)
 - Director of Nursing (required)
 - c. Infection Preventionist (required)
 - d. Consultant Pharmacist (required)
 - Additional member as deemed appropriate by the Antimicrobial Stewardship Committee which may include Nurse representative, Nursing Aide representative, QAPI Director, Administrator or other healthcare workers

Meetings

Antimicrobial Stewardship Committee will meet at least quarterly to review ASP-related activities and outcomes. The committee will also report its activities along with antibiotic use and resistance data to QAPI Committee at least on an annual basis.

3. Responsibilities

 Ensure appropriate use of antimicrobials through development and implementation of institutional policies, procedures, treatment algorithms, or other relevant initiatives



https://asap.nebraskamed.com/long-term-care/toolstemplates-long-term-care/



FORM AN ANTIBIOTIC STEWARDSHIP COMMITTEE/TEAM

Required

- Infection Preventionist
- Medical Director or a designated lead physician
- Director of Nursing or Assistant Director of Nursing
- Consultant Pharmacist

Optional

- Administrator
- Prescribing Provider (Attending Physician, Nurse Practitioner or Physician Assistant)
- Nurse representative
- Nurse Aid representative
- Allied Health Professional
- Representative from the Resident and Family Council

Committee should meet at least quarterly and review policy/program annually and as needed

Task Antibiotic Stewardship Committee with Specific Responsibilities

Antibiotic Stewardship Committee should:


- Support and promote antibiotic use protocols
- Develop and maintain a system to monitor antibiotic use
- Develop and maintain a system to monitor resistance data
- Report antibiotic use and resistance data regularly to frontline staff and prescribing providers along with goals of antibiotic stewardship programs
- Provide education on antibiotic stewardship to prescribing providers and nursing staff in addition to residents and families


Antibiotic use protocols include:

- Requirement of specific dose, duration and indication with all antibiotic orders
- Introduction of standardized tools and criteria for assessment and communication of infections (tools may also include decision support algorithms)
- Guidance on prescribing based on national recommendations and facility specific data which also highlights choosing narrow-spectrum antibiotics whenever possible
- Emphasis on reassessment of empiric antibiotics after 2 to 3 days for appropriateness and necessity (Post-Prescribing Review or Antibiotic time out)

Antibiotic Use Protocols

Effectiveness of Assessment/ Communication Tool






Available Assessment/ Communication Tools

	Suspected LRI SB
Complete this form before contacting the residen	t's physician.
	Date/Time
Nursing Home Name	
Resident Name	Date of Birth
Physician/NP/PA	Phone
	Fax
Nurse	Facility Phone
Submitted by □ Phone □ Fax □ In Person □	Other
S Situation	

	Suspected SST SBA
Complete this form before co	ontacting the resident's physician. Date/Time
Nursing Home Name	
Resident Name	Date of Birth
Physician/NP/PA	Phone
	Fax
Nurse	Facility Phone
Submitted by □ Phone □	Fax In Person Other



https://www.ahrq.gov/nhguide/toolkits/determine-whether-to-treat/toolkit3-minimum-criteria.html

Please Fax Back To:

[Facility Logo]

Resident Label

S	Situation	
	I am concerned about a suspected UTI for the above	resident.
В	Incontinence DYes DNo If yes, i UTI in last 6 months DYes DNo If yes, I	□ Urethral □ Suprapubic is this new or worsening □Yes □No Date: Organism: Treatment: inary conditions; diabetes; receiving dialysis, anticoagulants): antibiotic use):
A	Assessment Vital signs: BP/ HR Resp. rate	Temp 0 ₂ Sats
	Resident WITH indwelling catheter The criteria are met to initiate antibiotics if one of the following are selected: No Yes Fever of 100°F (38°C), or 2°F (1.1°C) above baseline, or repeated temperatures of 99°F (37°C) New back or flank pain Rigors / shaking / chills New onset delirium (new dramatic change in mental status) Hypotension (significant change in baseline BP or SBP <90) Acute suprapubic pain Acute pain, swelling or tenderness of the scrotal area	Resident WITHOUT indwelling catheter Criteria are met to initiate antibiotics if one of the three situations are met: No Yes Any one of the following two: Acute dysuria alone (pain or burning while urinating) Acute pain, swelling or tenderness of the scrotal area OR Single temp of 100°F (38°C), or 2°F (1.1°C) above baseline, or repeated temperatures of 99°F (37°C) and at least one of the following new or worsening symptoms: Urgency Suprapubic pain Frequency Gross hematuria Back or flank pain Urinary incontinence OR No fever, but two or more of the following new or worsening symptoms: Urgency Suprapubic pain Frequency Gross hematuria Urinary incontinence
R	Recommendation □ Protocol criteria met. Resident may require UA and	d urine culture or an antibiotic.
\Box	□ Protocol criteria are NOT met. Resident <u>DOES NOT</u>	need immediate antibiotic but may need additional observation.
	Nurse's Signature:	Date/Time:
	□ Notification of Family/POA Name:	Date/Time:
	□ Faxed or □ Called to:	By: Date/Time:
	Physician Orders, see reviewed the above SBAR.	/Response (Please check all that apply)
	ne culture (if indicated) courage 4oz of cranberry juice or another liquid (\TID until symptoms resolve
		put can also be measured from urinal or by weighing diapers, etc.)
	ess vital signs, including temp; every hours	
	enitor and notify PCP if symptoms worsen or unresolve	d in hours
□ Oth	ner: · antibiotic orders (if needed) please complete script be	elow:
Dru	ug: Dose: Route:	Frequency: Duration: Indication:
	ician Signature:	Date/Time:
1	=	

File Under Physician Order/Progress Notes



or

Telephone Order

Some facilities prefer to send a single page fax to the provider instead of a two-page form.

UTI SBAR

A modified single page version of communication tool for suspected UTI is available at Nebraska ASAP Website.

https://asap.nebraskamed.com/long-term-care/tools-templates-long-termcare The North West London Hospitals NHS

RAMP* Form Part B: Review of treatment

*Resident Antimicrobial Management Plan (part of StAUNCH Project)

Part B: Start to fill in 48-72 hours after commencing treatment All sections should be completed by end of treatment period

	Plan no. Resident Name Room no.									
G	ood Practice Points	Nurse Records								
B 1	Time: [24 hr dock] Date: / / The resident: [tick all applicable] now has no signs or symptoms of infection has improved remains the same has new signs / symptoms [state details]									
B 2	Stop date of treatment confirmed or review date planned	Total number of days treatment prescribed:		<i>/</i>	Sign & Date					
B 3	Resident re-examined by a doctor	Resident re-examined by a doctor for the <u>same</u> condition? YES / NO If YES was this: Scheduled GP visit Extra GP visit Out of Hours Serve Hospital A&E visit Hospital Admission Hospital Out-P			Sign & Date					
B 4	Results of samples / swabs recorded	Sample results: [tick all applicable] See section A4 overleaf No new samples or swabs sent before this treatment started Results not available yet Negative result (no growth) Positive result (micro-organisms grown) [state details if known] If positive result: Is this micro-organism sensitive to the antimicrobial presc [tick one option] Yes No Don't know Not tested in	ribed	d?	Sign & Date					
B 5	Outcome of antimicrobial treatment documented	Treatment outcome (at end of course) Symptoms completely resolved Symptoms partly resolved No improvement Additional antimicrobial treatment prescribed? YES / NO If YES: Commence ne	w RA	AMP form	Sign & Date					
	Tot Study Ose Only	Net. 110.		50						

Post – Prescribing Review of Antibiotics

- o Cluster RCT in 30 NHs in United Kingdom
- Introduced a form with Part A to be filled out at the start of antibiotic and Part B after 48 hour of treatment
- No additional intervention
- Part A was filled 86% of time and Part B 57% of time
- Antibiotic starts unchanged
- Antibiotic utilization decreased by 10%

Education of Nursing Staff and Providers

o Cluster RCT in 58 NHs in Sweden

- Prescribing guideline disseminated through interactive case-based sessions w/ nurses & providers
- Total antibiotic prescriptions decreased and wait and see approach by physicians increased



Tracking and Monitoring Antibiotic Use

Require review of antibiotics:

- On admission to and transfer out of the facility.
- When it is prescribed by a provider not on facility's staff (like ED provider)
- Of all ongoing and completed courses of antibiotics by consultant

Periodic (quarterly) Tracking of adherence to antibiotic use protocols

Conduct at least an annual review of antibiotic use data in the facility to identify:

- Specific antibiotic that is being excessively used or
- Providers who are using excessive antibiotics as compared to their peers.

Reach out to pharmacy to provide antibiotic use data and/or use infection/ antibiotic start log to obtain antibiotic use measurements like:


- Antibiotic starts/ 1000 resident days
- Days of therapy/ 1000 resident days

ection and Antibiotic Start Log Template



rameter	Jan -	Feb ~	Mar ~	Apr ~	May ~	Jun ~	Jul ~	Aug ~	Sep -	Oct ~	Nov ~	Dec ~	Total ~	Trend ~
ntibiotic Start / 1000 RD	11.29	7.14	7.98	3.99	5.88	9.78	6.67	8.42	2.44	3.76	5.56	5.56	78.46	m
ays of Therapy / 1000 RD	69.35	38.78	41.87	29.91	56.47	80.43	34.29	58.95	37.80	65.73	53.33	53.33	620.25	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
sed Assessment Tool	86%	86%	75%	75%	100%	78%	86%	75%	100%	75%	80%	80%	83%	~^^
let Criteria to Start ABX	67%	50%	50%	33%	100%	71%	50%	50%	100%	100%	100%	100%	73%	~~~
A, reflex C&S / 1000 RD	2.42	3.06	2.99	2.99	3.53	3.26	2.86	3.16	0.00	0.94	3.33	2.22	30.76	~~~

Antibiotic Use and Infection Assessment Trends



Tracking and Monitoring Resistance Data

Perform at least annual review of surveillance data pertaining to microorganisms related to antibiotic use like:

- Methicillin-resistant *Staphylococcus aureus*
- Carbapenemase-resistant *Enterobacteriaceae*
- Clostridium difficile
- Any other drug resistant organism that a facility seems to be struggling with

Make sure that the facility's contract with laboratory includes provision of facility specific antibiogram

Resistance data/ antibiogram should also be considered when developing facility specific antibiotic use guidance

Reporting/ Feedback Process

Antibiotic Stewardship Committee/ team will be part of Infection Control and Prevention Program (IPCP).

It will report progress to the Quality Assessment and Assurance (QAA) Committee at least annually

New CMS rules mandate IPCP to be reviewed at least annually.

In addition to QAA committee, annual written feedback on facilty's antibiotic use and resistance data should be shared with:


- Prescribing providers
- Nursing Staff
- Administration
- Resident and Family Council

Provide written feedback on antibiotic use for each provider on an annual basis

Also share facility specific antibiograms with all the prescribing providers

Use of Nursing Home Antibiogram

- OUp to 85% of treatment started empirically
- Where cultures available
 - only 32% of empiric antibiotic appropriate
- Antibiogram was distributed to Nursing Staff, Administrators and Physicians in a meeting.
- o 6 months later there was a modest increase in appropriateness; however, the difference was not statistically significant



[Facility Logo]

Antibiotic Susceptibility Report for Most Frequently Isolated Gram-Negative Organisms (January 2015 to December 2016)

		Percent Susceptible																			
Pathogen	Isolate Tested	Ampicillin	Ampicillin/Sulbactam	Piperacillin/Tazobactam	Cefazolin	Cefepime	Cefexitin	Ceftazidime	Ceftriaxone	Cefuroxime	Aztreonam	Ertapenem	Meropenem	Amikacin	Gentamicin	Tobramycin	Ciprofloxacin	Levofloxacin	Trimethoprim/Sulfa	Nitrofurantoin ¹	Tetracycline
Escherichia coli	111	53	59	99	86	98	92	98	97	91	98	100	100	100	91	91	58	59	76	99	77
Klebsiella pneumoniae	41		78	98	93	98	95	98	98	93	98	100	100	100	98	98	95	95	93	63	83
Proteus mirabilis	41	98	98	100	100	100	100	100	100	100	100	100	100	100	100	75	75	75	75	50	75
Pseudomonas aeruginosa	31			97		97		97			84		90	100	74	77	71	71			

-- Denotes organism has intrinsic resistance to this antimicrobial

1. Nitrofurantoin is reported for urine sources only

Summary for Gram-Negative Organisms

During the 2-year period between January 2015 and December 2016, a total of 111 E coli were identified, making it the most commonly identified Gramnegative pathogen. Antibiotic susceptibility of these E coli can be summarized as follow:

- 1. Oral antibiotics with the highest susceptibilities (in descending order) were:
 - a. Nitrofurantoin (99%)
 - b. Cefuroxime (91%)
 - c. Cephalexin (86%, as indicated by cefazolin susceptibility)
 - Trimethoprim/sulfamethoxazole (76%)
- 2. Susceptibilities of antibiotics available only in intravenous formulation (e.g., ceftriaxone) exceed 90%, except:
 - a. Ampicillin/sulbactam (59%)
 - b. Cefazolin (86%)

Antibiotic susceptibility data can be useful for guiding selection of empiric antibiotic therapy for residents in whom culture and susceptibility data from the past few months are not available.



[Facility Logo]

Quarterly Antimicrobial Use Summary Report

This report summarizes all systemic antibiotics (IV, IM, PO) prescribed between [month/year] to [month/year]. A total number of [aa] antibiotic courses in [bb] patients were reviewed. During this three-month period, a total of [cc] antibiotic starts / 1000 resident-days (RD) and [dd] days of therapy (DOT) / 1000 RD were observed. The most common reasons for starting antibiotic therapy were [top 3 infectious syndromes]. The three most frequently prescribed antibiotics were [antibiotic names]. Of all the antibiotic courses initiated during this period, [ee]% of courses of therapy were appropriate based on [McGeer, Loeb] criteria. The table below further details antibiotic prescribing patterns and appropriateness during this period.

Cumulative Antimicrobial Use Summary Report for 20[XX]

Quarter	New Antibiotic Start / 1000 RD	DOT / 1000 RD	Top 3 Antibiotics with highest DOT / 1000 RD	Top 3 Indications for Starting Antibiotic Therapy	Met Criteria for Initiating Antibiotic Therapy
First Quarter: January to March	[cc]	[dd]	Ciprofloxacin (ff DOT/1000 RD) Cephalexin (gg DOT/1000 RD) Amoxicillin (hh DOT/1000 RD)	UTI (ii %) SSTI (jj %) ARI (kk %)	UTI (II %) SSTI (mm %) ARI (nn %) Overall [ee]%
Second Quarter: April to June					
Third Quarter: July to September					
Fourth Quarter: October to December					

Abbreviations: RD = resident-day; DOT = days of therapy; UTI = urinary tract infection; SSTI = skin and soft tissue infection; ARI = acute respiratory infection

Sample Antibiotic Use Summary Report is available at Nebraska ASAP website

https://asap.nebraskamed.com/longterm-care/tools-templates-long-termcare



Education


- Nursing staff
- Prescribing providers
- Families
- Residents
- Resident and Family Council

- Need of antibiotic stewardship program and its goals
- Understanding of antibiotic use protocols
- Responsibility of each healthcare worker for ensuring its implementation.

- Dangers of antibiotic misuse
- Role of antibiotic stewardship program in promoting appropriate antibiotic use

Impact of On-Line Course for Nurses





After the course, nurses' agreement that their role influences whether residents receive antimicrobials also increased significantly

ANTIMICROBIAL STEWARDSHIP PROGRAM

What is an Antimicrobial Stewardship Program?

An Antimicrobial Stewardship Program is a set of systematic activities aimed to promote the appropriate use of antimicrobials. The program goals are to:

- Improve quality of patient care and patient outcomes
- Minimize side effects from antimicrobials
- ☐ Limit the development of antimicrobial resistance
- Educate providers on when to prescribe antimicrobials, and the right drug, dose and duration to use

Why is Antimicrobial Stewardship Program needed?

- ☐ Up to 75% of antimicrobial use is considered inappropriate
- ☐ Inappropriate use will increase antimicrobial resistance and lead to unwanted side effects (Clostridium difficile infection)
- An Antimicrobial Stewardship Program can improve patient outcomes and reduce inappropriate antimicrobial use








How can Antimicrobial Stewardship Program be implemented?

Practical steps of implementation include:

- 1. Obtain program support from facility leadership
- Partner with regional physicians or pharmacists with infectious diseases or antimicrobial stewardship expertise
- 3. Form an Antimicrobial Stewardship Committee
- 4. Review data on infection assessment practices, and antimicrobial use and resistance patterns
- Determine program goals such as the types and extents of interventions (e.g., use assessment tools for all suspected infections, eliminate treatment of asymptomatic bacteriuria)
- 6. Educate prescribers and staff on the types, reasons and goals of the selected interventions
- 7. Track outcomes after implementation of interventions
- 8. Report and educate program activities and outcomes to prescribers, staff and residents/families





Ideally everyone who is involved in the antibiotic use process:

- Medical Directors: set standards for antibiotic prescribing practices
- Directors of Nursing: set standards for nursing practices
- Infection Preventionists: be responsible for the Infection Prevention and Control Program and support Antimicrobial Stewardship Program activities
- Consultant Pharmacists: perform drug use review, provide antibiotic use data and assist with developing treatment guidelines
- Prescribers: prescribe antimicrobials only when clearly indicated
- Nursing staff: evaluate patient using standardized assessment tools and communicate patients' symptoms to prescribers









Content developed based on resources provided by the Centers for Disease Control and Prevention (CDC) retrieved October 2017 from https://www.cdc.gov/drugresistance/threat-report-2013/index.html and https://www.cdc.gov/longtermc.are/prevention/antibiotic-stewardship.html.

This educational poster and other educational materials can be found at Nebraska ASAP website at following link:

https://asap.nebraskamed.com/long-term-care/educational-materials-long-term-care/

Summary of the Steps

Obtain leadership statement of support

Establish accountability

Partner with local experts or develop expertise within the facility

Develop Antibiotic Stewardship Protocol

Form an Antibiotic Stewardship Committee/Team

Task Antibiotic Stewardship Committee with Specific Responsibilities

- Support and promote antibiotic use protocols
- Develop and maintain a system to monitor antibiotic use
- Develop and maintain a system to monitor resistance data
- Report antibiotic use and resistance data regularly to frontline staff and prescribing providers along with goals of antibiotic stewardship programs
- Provide education on antibiotic stewardship to prescribing providers and nursing staff in addition to residents and families



Putting Antibiotic Stewardship Infrastructure in Place

Resources for ASP

https://asap.nebraskamed.com Accessed June 22, 2018

http://www.cdc.gov/longtermcare/prevention/antibioticstewardship.html Accessed June 22, 2018

http://www.ahrq.gov/professionals/quality-patient-safety/patient-safety-resources/nh-aspguide/index.html Accessed June 22, 2018

https://nursinghomeinfections.unc.edu/Accessed June 22, 2018

http://www.rochesterpatientsafety.com/index.cfm?Page=For%20Nursing %20Homes

June 22, 2018

http://www.health.state.mn.us/divs/idepc/dtopics/antibioticresistance/asp/index.html

June 22, 2018

www.ahrq.gov/NH-ASPGuide

June 22, 2018



12 Common Nursing Home Situations in Which Systemic Antibiotics are Generally Not Indicated

- Positive urine culture in an asymptomatic resident.
- Urine culture ordered solely because of change in urine appearance.
- Nonspecific symptoms or signs not referable to the urinary tract, such as falls or mental status change (with or without a positive urine culture).
- Upper respiratory infection (common cold).
- Bronchitis or asthma in a resident who does not have COPD.
- "Infiltrate" on chest x-ray in the absence of clinically significant symptoms.
- Suspected or proven influenza in the absence of a secondary infection (but DO treat influenza with antivirals).
- Respiratory symptoms in a resident with advanced dementia, on palliative care, or at the end of life.
- Skin wound without cellulitis, sepsis, or osteomyelitis (regardless of culture result).
- Small (<5cm) localized abscess without significant surrounding cellulitis (drainage is required of all abscesses).
- Decubitus ulcer in a resident at the end of life.
- Acute vomiting and/or diarrhea in the absence of a positive culture for shigella or salmonella, or a positive toxin assay for Clostridium difficile.

Additional Resources for Educational Materials

This pocket card is available at:

https://www.ahrq.gov/sites/default/files/wysiwyg/nhguide/4_TK2_T2-Antibiotic_Pocket_Cards.pdf

Other Educational resources for physicians, nurses and families/ residents can be found at:

- https://asap.nebraskamed.com/long-term-care/educational-materials-long-term-care/
- http://www.health.state.mn.us/divs/idepc/dtopics/antibioticresistance/asp/ltc/
- https://nursinghomeinfections.unc.edu/
- https://www.cdc.gov/longtermcare/index.html
- www.ahrq.gov/NH-ASPGuide
- http://www.rochesterpatientsafety.com/index.cfm?Page=For%20Nursing%20Homes

Accessed June 22, 2018

Dissecting Data for Antibiotic Stewardship

Ask basic questions on antibiotic use:

- How much antibiotics are we using?
- For what reasons are we using antibiotics?
- Which antibiotics are we using the most?
- Who is prescribing antibiotics?
- What proportion of the use is

Broad Categories of Data Required for Antibiotic Stewardship Program

Antibiotic Use Measures

- Antibiotic Starts/ 1000 resident days
- Antibiotic days of therapy/1000 resident days

Process Measure

- Proportion of antibiotic orders with dose, duration and indication
- Proportion of antibiotic orders with related clinical documentation
- Proportion of antibiotic orders that meet standard criteria/guidelines

Outcome Measures

- Antimicrobial Resistance
- Antibiotic-associated adverse events
- *C. difficile* infections

Data Sources for Antibiotic Stewardship

Dispensing Pharmacy

Consultant Pharmacist

Microbiology Laboratory

Infection Preventionist

- Antibiotic starts
- Days of therapy
- Use by Class
- Use by Diagnosis
- Use by Provider
- Regional comparison

- Appropriateness of orders
- Orders meeting criteria/guidance
- Documentation compliance
- Bug-drug mismatches
- Adverse events

- Diagnostic test utilization
- Antibiogram
- List of positive test results for specific pathogens

- Antibiotic use information from infection log
- Infection rates
- Orders meeting standard criteria
- Nursing protocol compliance
- MDRO prevalence

Use

• Use a standardized approach in defining antibiotic appropriateness when performing surveillance:

Determine

• Determine whether meeting a standard criteria (such as Loeb's criteria)

Assess

• Assess whether facility protocol for prescribing is being followed (such as conditions for prescribing were met as per the adapted SBAR tool)

Evaluate

• Evaluate whether the order is consistent with published national guidelines or recommendations

Surveillance of Antibiotic Prescribing Practices

Published Guidance on Management of Common Infections

- <u>Diagnosis and Management of Skin and Soft Tissue Infection:</u> Stevens DL, et al. Clin Infect Dis 2014;59:e10-52
- Appropriate Antibiotic Use for Acute Respiratory Tract Infection in Adults: Harris AM, et al. Ann Intern Med 2016.
- Management of Community-Acquired Pneumonia in Adults: Mandell LA, et al.
 Clin Infect Dis 2007;44;S27-72.
- <u>Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women:</u> Gupta K et al. Clin Infect Dis 2011;52:e103-20.
- <u>Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults:</u> Hooton TM, et al. Clin Infect Dis 2010;50:625-63.
- <u>Diagnosis of Uncomplicated Cystitis in Nursing Home Residents</u>: Nace DA et al. J Am Med Dir Assoc. 2018 Sep;19(9):765-769.e3
- Decision Tool for the Empiric Treatment of Suspected Urinary Tract Infection in Frail Older Adults: van Buul LM et al. J Am Med Dir Assoc. 2018 Sep;19(9):757-764

Table 1. Recommended Durat Infection Syndrome	Typical Duration of Therapy
Uncomplicated cystitis ^{1,2}	5 days for Nitrofurantoin
Uncomplicated cystitis	3 days for TMP/SMX
	1 dose for Fosfomycin
	3 days for Fluoroquinolones
	3-7 days for Beta-Lactams
Pyelonephritis ¹	7 days for Fluoroquinolones
	14 days for TMP/SMX
	10-14 days for Beta-Lactams
Catheter-associated urinary tract	7 days if prompt resolution of symptoms
infection ³ or complicated* UTI ^{2,4}	10-14 days if delayed response to therapy
Pneumonia ^s	5-7 days
Bronchitis ^{6,7}	No antibiotic therapy is recommended
Acute exacerbation of COPD®	5 days if treatment criteria met
Influenza ^{9,10}	5 days for treatment
	Minimum of 2 weeks, continuing for at least 7 days after
	the last known case was identified for
	chemoprophylaxis in influenza outbreak
Pharyngitis, streptococcal ¹¹	Up to 10 days for penicillin, amoxicillin, 1st-generation oral
	cephalosporins, clindamycin
	5 days for azithromycin
Sinusitis ¹²	5-7 days if improvement after 3-5 days of treatment
	7- 10 days if delayed response or switched to alternative
	therapy due to lack of response
Cellulitis or cutaneous abscess ¹³	5-7 days
Shingles ¹⁴	7 days for famciclovir, valacyclovir
	7-10 days for acyclovir
Clostridium difficile infection ¹⁵	10-14 days
	10 days for fidaxomicin
Gastroenteritis, bacterial ¹⁶	3-5 days if treatment criteria met

^{*} Refer to Table 2 for factors associated with complicated UTI.



of therapy recommendations from various guidelines along with all the references is available at Nebraska ASAP Website.

https://asap.nebraskamed.com/longterm-care/guidance-document-longterm-care/

Loeb's Criteria Checklist for Surveillance

Patient Name:	MRN:	Location:	
Date of Infection:	Date of Review:	Reviewed by:	
UTI: a evaluated a criteria met	RTI: 🗆 evaluated 🗆 criteria met	SSTI: □ evaluated □ criteria met	FUO: a evaluated a criteria met
Suspected Infection Syndrome	Minimum Criteria for Starting Antibioti	c Therapy	
Urinary tract infection without catheter with catheter	At least one of the following criteria	g symptoms Frequency	C (2.4 °F) above baseline
Note: Residents with intermittent catheteriz Urine culture should be sent prior to s Antibiotics should not be started for c	tarting antibiotics	orized as 'without catheter'	
Lower respiratory tract infection with temp >38.9 °C (102 °F)	 Productive cough 	□ Respiratory rate >25 breaths / n	
with temp >37.9 °C (100 °F) or 1.5 °C (2.4 °F) above baseline	Both of the following criteria Cough, AND At least one of the following criteria Pulse >100 beats / minutes Rigors		
afebrile with COPD and >65 years old	Both of the following criteria		

afebrile without COPD	All of the following criteria New cough Purulent sputum production
	At least one of the following criteria
	□ Delirium □ Respiratory rate >25 breaths / minute
with new infiltrate on chest	At least one of the following criteria
X-ray consistent with pneumonia	□ Productive cough □ Temp >37.9 °C (100 °F) or 1.5 °C (2.4 °F) above baseline □ Respiratory rate >25 breaths / minute
Note: Consider ordering chest X-ray and CBC	L Cwith differential for febrile residents with cough and any of these criteria (HR >100, worsening mental status, or rigors)
Antibiotics should not be used for up t	to 24 h after large-volume aspiration in those without COPD but with temp ≤38.9ºC (102 ºF) and non-productive cough
Skin and soft-tissue infection	Either one of the following criteria
	□ New or increasing purulent drainage, OR
	At least two of the following criteria
	☐ Redness (erythema) ☐ Temp >37.9 °C (100 °F) or 1.5 °C (2.4 °F) above baseline
	□ Tenderness □ New or increasing swelling at affected site
	□ Warmth
Note: These criteria do not apply to resident	ts with burns
Surgical consultation and hospitalizati	ion are required for certain soft-tissue infections (e.g., necrotizing fasciitis or gas gangrene)
	Both of the following criteria
Fever where the Focus of Infection is	east of the following criteria
	□ Temp >37.9 °C (100 °F) or 1.5 °C (2.4 °F) above baseline, AND
	□ Temp >37.9 °C (100 °F) or 1.5 °C (2.4 °F) above baseline, AND
Fever where the Focus of Infection is Unknown	-
	□ Temp >37.9 °C (100 °F) or 1.5 °C (2.4 °F) above baseline, AND □ At least one of the following criteria
Unknown	□ Temp >37.9 °C (100 °F) or 1.5 °C (2.4 °F) above baseline, AND □ At least one of the following criteria


Loeb M, et al. Infect Control Hosp Epidemiol

2001;22:120-4

https://asap.nebraskamed.com/long-term-care/tools-templates-long-term-care/



Comparing Antibiotic Use Among Regional LTCF



Template for Tracking Antibiotic Use

								0						
					Days of				Culture f/u at			Community	Assessment / SBAR	Criteria
Room 🔻	Diagnosis 🔽	Antibiotic	Start Date 🔽	Stop Date	Therapy -	Prescriber -	Lab Sent	Test Date 🔻	48-72h? ▼	Pathogen	Result Date 🔻	vs. Facility 🔻	Tool Completed? 🔻	Met? ▼
135B	UTI	nitrofurantoin	1/2/16	1/4/16	3	Dr. Lexin	UA, reflex C&S	1/30/16	Yes	Proteus mirabilis	1/2/16	Facility	Yes	No
156A	SSTI	cephalexin	1/15/16	1/21/16	7	PA Cillin	None	NA	NA	NA	NA	Facility	Yes	Yes
251B	UTI	ciprofloxacin	1/1/16	1/14/16	14	PA Cillin	UA, reflex C&S	1/30/16	Yes	E coli	2/1/16	Community	No	No
551A	Pneumonia	azithromycin	1/20/16	1/26/16	7	Dr. Lexin	None	NA	NA	NA	NA	Community	Yes	Yes
551A	UTI	nitrofurantoin	1/3/16	1/5/16	3	Dr. Lexin	UA, reflex C&S	1/3/16	Yes	E coli	1/5/16	Community	Yes	No
431B	Pneumonia	azithromycin	1/20/16	1/24/16	5	Dr. Peni	None	NA	NA	NA	NA	Community	Yes	Yes
431B	Pneumonia	amoxicillin-clavulanate	1/20/16	1/24/16	5	Dr. Peni	None	NA	NA	NA	NA	Community	Yes	Yes
251B	C difficile	vancomycin po	1/14/16	1/23/16	10	PA Cillin	C difficile PCR	1/13/16	No	C difficile	1/18/16	Facility	No	Yes
301A	Influenza	oseltamivir	1/1/16	1/5/16	5	Dr. Gripe	Flu swab	1/1/16	Yes	Influenza A	1/1/16	Facility	Yes	Yes
301B	Influenza	oseltamivir	1/2/16	1/6/16	5	Dr. Gripe	Flu swab	1/2/16	Yes	Influenza A	1/2/16	Facility	Yes	Yes
302A	Influenza	oseltamivir	1/1/16	1/5/16	5	Dr. Gripe	Flu swab	1/1/16	Yes	Influenza A	1/1/16	Facility	Yes	Yes
303A	Influenza	oseltamivir	1/1/16	1/5/16	5	Dr. Gripe	Flu swab	1/1/16	Yes	Negative	1/1/16	Facility	Yes	No
303B	Influenza	oseltamivir	1/1/16	1/5/16	5	Dr. Gripe	Flu swab	1/1/16	Yes	Negative	1/1/16	Facility	Yes	No
303B	Pneumonia	levofloxacin	1/2/16	1/8/16	7	Dr. Gripe	None	NA	NA	NA	NA	Facility	Yes	Yes
Column "R" will automatically update in this tab and in the Summary tab. Different Antibiotic Tracking Template along with some other tools can also be found the behavior of the column that the summary tab. Different Antibiotic Tracking Template along with some other tools can also be found the column that the summary tab. http://www.rochesterpatientsafety.com/index.cfm?Page=For%20Nursing%20Ho								also be foun	nd at:					
	135B 156A 251B 551A 551A 431B 431B 251B 301A 301B 302A 303A 303B	135B UTI 156A SSTI 251B UTI 551A Pneumonia 551A UTI 431B Pneumonia 431B Pneumonia 251B C difficile 301A Influenza 301B Influenza 302A Influenza 303A Influenza 303B Pneumonia Type addition row. Summa column "R" w	Room ▼ Diagnosis ▼ Antibiotic ▼ 135B UTI nitrofurantoin 156A SSTI cephalexin 251B UTI ciprofloxacin 551A Pneumonia azithromycin 551A UTI nitrofurantoin 431B Pneumonia azithromycin 431B Pneumonia amoxicillin-clavulanate 251B C difficile vancomycin po 301A Influenza oseltamivir 301B Influenza oseltamivir 302A Influenza oseltamivir 303A Influenza oseltamivir 303B Pneumonia levofloxacin Type additional antibiotic start in the norow. Summary 1 & 2 data to the right column "R" will automatically update in	Room Diagnosis Antibiotic Start Date 135B UTI nitrofurantoin 1/2/16 156A SSTI cephalexin 1/15/16 251B UTI ciprofloxacin 1/1/16 551A Pneumonia azithromycin 1/20/16 551A UTI nitrofurantoin 1/3/16 431B Pneumonia azithromycin 1/20/16 431B Pneumonia amoxicillin-clavulanate 1/20/16 251B C difficile vancomycin po 1/14/16 301A Influenza oseltamivir 1/1/16 301B Influenza oseltamivir 1/2/16 302A Influenza oseltamivir 1/1/16 303B Influenza oseltamivir 1/1/16 303B Influenza oseltamivir 1/1/16 303B Pneumonia levofloxacin 1/2/16 Type additional antibiotic start in the next row. Summary 1 & 2 data to the right of column "R" will automatically update in this	Room ▼ Diagnosis ▼ Antibiotic ▼ Start Date ▼ Stop Date ▼ 135B UTI nitrofurantoin 1/2/16 1/4/16 156A SSTI cephalexin 1/15/16 1/21/16 1/21/16 251B UTI ciprofloxacin 1/1/16 1/14/16 1551A Pneumonia azithromycin 1/20/16 1/26/16 551A UTI nitrofurantoin 1/3/16 1/5/16 1/5/16 431B Pneumonia azithromycin 1/20/16 1/24/16 1/24/16 1/251B C difficile vancomycin po 1/14/16 1/23/16 301A Influenza oseltamivir 1/1/16 1/5/16 302A Influenza oseltamivir 1/2/16 1/6/16 303A Influenza oseltamivir 1/1/16 1/5/16 303B Pneumonia levofloxacin 1/2/16 1/8/16	Room Diagnosis Antibiotic Start Date Stop Date Therapy 135B UTI nitrofurantoin 1/2/16 1/4/16 3 156A SSTI cephalexin 1/15/16 1/21/16 7 251B UTI ciprofloxacin 1/1/16 1/26/16 7 551A Pneumonia azithromycin 1/20/16 1/26/16 7 551A UTI nitrofurantoin 1/3/16 1/5/16 3 431B Pneumonia azithromycin 1/20/16 1/24/16 5 431B Pneumonia amoxicillin-clavulanate 1/20/16 1/24/16 5 251B C difficile vancomycin po 1/14/16 1/23/16 10 301A Influenza oseltamivir 1/1/16 1/5/16 5 301B Influenza oseltamivir 1/2/16 1/6/16 5 302A Influenza oseltamivir 1/1/16 1/5/16 5 303A Influenza oseltamivir 1/1/16 1/5/16 5 303B Pneumonia levofloxacin 1/2/16 1/8/16 7	Room Diagnosis Antibiotic Start Date Stop Date Therapy Prescriber Days of Days of Therapy Prescriber Days of Days of Therapy Prescriber Days of Da	Room Diagnosis Antibiotic Start Date Stop Date Therapy Prescriber Lab Sent 135B UTI nitrofurantoin 1/2/16 1/4/16 3 Dr. Lexin UA, reflex C&S 156A SSTI cephalexin 1/15/16 1/21/16 7 PA Cillin UA, reflex C&S 151B UTI ciprofloxacin 1/1/16 1/20/16 1/26/16 7 Dr. Lexin None 151A UTI nitrofurantoin 1/3/16 1/5/16 3 Dr. Lexin None 151A UTI nitrofurantoin 1/3/16 1/5/16 3 Dr. Lexin None 1/20/16 1/24/16 5 Dr. Peni None 1/20/16 1/24/16 5 Dr. Peni None 1/20/16 1/24/16 5 Dr. Peni None 1/20/16 1/24/16 5 Dr. Gripe 1/20/16 1/24/16 5 Dr. Gripe 1/20/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21/16 1/21	Room Diagnosis Antibiotic Start Date Stop Date Therapy Prescriber Lab Sent Test Date 135B UTI nitrofurantoin 1/2/16 1/4/16 3 Dr. Lexin UA, reflex C&S 1/30/16 156A SSTI cephalexin 1/15/16 1/21/16 7 PA Cillin None NA 251B UTI ciprofloxacin 1/1/16 1/26/16 7 Dr. Lexin None NA 251A Pneumonia azithromycin 1/20/16 1/26/16 7 Dr. Lexin None NA 251A UTI nitrofurantoin 1/3/16 1/5/16 3 Dr. Lexin UA, reflex C&S 1/3/16 1/3/16 1/5/16 3 Dr. Lexin None NA 241B Pneumonia azithromycin 1/20/16 1/24/16 5 Dr. Peni None NA 251B C difficile vancomycin po 1/14/16 1/23/16 10 PA Cillin C difficile PCR 1/13/16 301A Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303A Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/2/16 303A Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B Influenza Oseltamivir 1/1/16 1/5/16 5 Dr. Gripe Flu swab 1/1/16 303B In	Days of Diagnosis Antibiotic Start Date Stop Date Therapy Prescriber Lab Sent Test Date 48-72h? 135B UTI nitrofurantoin 1/2/16 1/4/16 3 Dr. Lexin UA, reflex C&S 1/30/16 Yes 156A SSTI cephalexin 1/15/16 1/21/16 7 PA Cillin None NA NA NA NA NA NA NA N	Boom	Room Diagnosis Antibiotic Start Date Stop Date Therapy Prescriber Lab Sent Test Date A8-72h? Pathogen Result Date 1558 UTI nitrofurantoin 1/2/16 1/4/16 3 Dr. Lexin UA, reflex C&S 1/30/16 Yes Proteus mirabilis 1/2/16 1/5/16 1/21/15 7 PA Cillin UA, reflex C&S 1/30/16 Yes E coli 2/1/16 1/5/16 1/14/16 14 PA Cillin UA, reflex C&S 1/30/16 Yes E coli 2/1/16 1/5/14 Pa Cillin UA, reflex C&S 1/30/16 Yes E coli 2/1/16 1/5/14 Pa Cillin UA, reflex C&S 1/30/16 Yes E coli 2/1/16 1/5/16 1/14/16 1/5/16 3 Dr. Lexin None NA	Day of D	Room Diagnosis Antibiotic Start Date Stop Date Therapy Prescriber Lab Sent Test Date 48-72h? Pathogen Result Date vs. Facility Tool Completed? 1958 UTI nitrofurantoin 1/2/16 1/4/16 3 Dr. Lexin UA, reflex C85 1/30/16 Yes Protesus mirabilis 1/2/16 Facility Yes 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16 1/14/16


Summary Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec


Examples of Reports Generated by the Excel Sheet


Infection and Antibiotic Start Log Template, Version 3




Year = 2018																					_		
Parameters	Jan	¥	Feb	v	Mar	v	Apr ▼	May	w	Jun 1	ا ا	Jul ▼	Α	ug	*	Sep ▼	Oct ₹	Nov ▼	Dec	¥	Average 🔻	Trend	w
Antibiotic Start / 1000 RD	11.2	9	7.14		7.98		3.99	5.88		9.78		6.67		8.42		2.44	3.76	5.56	5.5	6	6.54	W~	~~
Days of Therapy / 1000 RD	69.3	5	38.78		41.87		29.91	56.47		80.43		34.29		58.95		37.80	65.73	53.33	53.	33	51.69	\checkmark	~~
SBAR Used and Completed	86%	6	71%		63%		75%	100%	,	78%		86%		75%		100%	75%	80%	80	%	81%	\checkmark	^-
Met Criteria to Start AB	67%	6	40%		80%		33%	100%	,	71%		50%		50%		100%	100%	100%	100	0%	74%	W\	/










One-Day Point Prevalence Method for Tracking Antibiotic Use

- Useful in estimating antibiotic days of therapy
- Requires antibiotic tracking on one day of the week only
- Gives an estimate but not exact use
- Use the following equation to estimate days of therapy

$$\frac{\sum Wednesday\ Point\ Prevalence\ AU}{(Average\ Daily\ Census*\ Number\ of\ Wednesdays\ in\ Month)}*1,000$$



Understanding and Creating Antibiogram

Guidelines on creating antibiograms recommends to:

- report antibiogram at least annually
- include only verified final results
- include only species with data for 30 isolates
- include only diagnostic (not surveillance) isolates
- include the first isolate of a species obtained from a patient for each analysis period

Hypothetical Healthcare Facility 1 January-31 December 2017 Cumulative Antimicrobial Susceptibility Report+ Percent Susceptible

			8.200.000							
Gram (-) Organisms	# of Isolates	Amoxicillin/ Clavulanate	Cefazolin	Ceftriaxone	Cefepime	Nitrofurantoin	Piperacillin/ Tazobactam	Ciprofloxacin	Gentamicin	TMP/SMX
Escherichia coli	39	84	64	74	89	100	87	26	82	85
Klebsiella pneumoniae	17*	76	76	82	100	65	88	94	88	76
Proteus mirabilis	32	95	53	88	100	R	97	16	100	81
Pseudomonas aeruginosa	11*		R		73	-	57	64	64	
Gram (+) Organisms	# of Isolates	Ampicillin	Clindamycin	Oxacillin	Gentamicin	Linezolid	Nitrofurantoin	Tetracycline	TMP/SMX	Vancomycin
Staphylococcus aureus	19*		50	36	79	100	100	79	100	93
Enterococcus	35	83		82.4	52	100	81	17	122	83

Approaches to Creating an Antibiogram with Limited Isolates

Table 1Advantages and Limitations of the Potential Approaches to Creating a LTCF Antibiogram

Approach		
Extending the antibiogram data beyond 1 year	Advantages	Simple and easy to create Accurate susceptibilities over the given time period
POST 1 1 Process (Comments of the Comments of	Limitation	 Resistance rates and patterns of bacteria may change from year to year
Creating a regional	Advantage	 May be helpful if residents access healthcare facilities throughout that given region
antibiogram	Limitations	 Requires coordination between multiple microbiology laboratories and healthcare facilities
		 Bacteria that infect residents may not have similar antimicrobial susceptibilities to those of that region's general population
Using antibiograms	Advantage	 Antibiograms that are already annually made by the hospitals could be used
of nearby hospitals	Limitations	All residents go to different hospitals
		 Bacteria that infect LTCF residents may not have similar antimicrobial susceptibilities to those of the general hospital population
Collapsed antibiograms	Advantage	 May help guide infection-specific empiric antibiotic choices
	Limitation	 Intrinsic resistance of some bacteria to specific antibiotics would not be listed

Using Baseline Data to Form an Action Plan

Antibiotic Use Measures	Rate
Antibiotic Starts	7.35/1000 resident days
Days of Therapy	57.51/1000 resident days

Indications	Number (%)
Urinary tract infection	39 (35)
Skin/soft-tissue infection	28 (25)
Respiratory tract infection	9
No indication	8
Pneumonia	6
Gastrointestinal infection	4
COPD	3
Fever	2
Urinary tract infection prophylaxis	2
Others	9

Most frequently used antibiotics	Number (%)				
Ciprofloxacin/Levofloxacin	27 (22)				
Cephalexin	26 (21)				
Nitrofurantoin	18 (15)				
Doxycycline	11 (9)				
Others	42 (34)				

Met criteria to start antibiotic— 16 (41%) Didn't Meet criteria - 23 (59%)

- ☐ What are the top improvement opportunities?
- ☐ What Actions would you like to take?

Antibiotic Time-Out

Goals are to determine:

- Whether initial symptoms were due to bacterial infection that requires antibiotic?
- If yes, is the current antimicrobial treatment appropriate (e.g ruling out bugdrug mismatch, reconfirming agent, dose, route)?
- Can antibiotics be deescalated?
- What will be the length of therapy?
- Is further evaluation required?

https://asap.nebraskamed.com/long-term-care/tools-templates-long-term-care/

https://www.cdc.gov/longtermcare/pdfs/core-elements-antibiotic-stewardship-appendix-a.pdf

SBAR Communication Tool Template for Antibiotic Time-Out

[Facility Logo]

Resident Label

S	Situation: I am calling to follow-up on [resident's name:] who was started on antibiotic(s) recently.
В	Background: This patient was started on:
_	Antibiotic #1: Start date:
	Antibiotic #2: Start date:
	For: UTI Pneumonia Bronchitis Skin infection Gl infection
	☐Fever of unknown source ☐Other, specify:
	Vitals at initial presentation were as follows: BP/ HR Resp. rate Temp 0 ₂ Sats
	Symptoms and positive exam findings at that time were:
	The diagnosis fits: ☐McGeer criteria ☐Loeb criteria ☐Neither ☐Assessment tool not used
Α	Assessment:
٠.	Current vital signs: BP/ HR Resp. rate Temp 0 ₂ Sats
	Since starting antibiotic(s), the resident:
	□now has <u>no</u> signs or symptoms of infection □has remained the same
	□has improved but continues to have signs and symptoms of:
	□has <u>new or worsening</u> signs/symptoms of:
	Microbiology culture result (fax microbiology report if available):
	□has not returned yet □has <u>no</u> growth □was not obtained
	□has positive Gram stain/growth of [specify Gram stain/microorganism:]
	Is susceptible to the antibiotic(s) prescribed: Yes No Don't know
	□Not tested by lab □Not yet performed by lab
	Other antibiotics the organism is sensitive to:
R	Recommendation:
	Patient is not improving and needs further evaluation.
	Patient has improved and needs final antibiotic therapy plan.
	Nurse's Signature: Date/Time:
	□Faxed or □Called to:By:Date/Time:

Example of Provider Feedback

PMNH Antibiotic Report Card for Treatment of Respiratory Infection, 2014

Provider	Antibiotic starts	Appropriate	Not appropriate*	Percent not appropriate
Provider 1	38	36	2	5.3
Provider 2	24	23	1	4.2
Provider 3	8	6	2	25
Provider 4	2	2	0	0
Provider 5	0	0	0	0
PMNH cumulative	72	67	5	6.9

This facility was highlighted in a report for successfully implementing ASP.

Multiple interventions were implemented including communication tools, vigorous review of antibiotic orders and introducing antibiograms

However, one of the main interventions were to provide Feedback to the providers in addition to one on one discussions by medical director

Nursing home residents' clinical symptoms met the McGeer Surveillance Criteria for diagnosis of viral respiratory infection.

^{© 2016} The Pew Charitable Trusts

Choosing the Right Intervention

Target for Intervention	Intervention	Provide relevan
Antibiotics being prescribed even when clinical criteria for infection are not met	SBAR tool implementation	education to nu staff and prescu about the inter
Diagnostic tests being sent unnecessarily	SBAR tool implementationUse of Decision-making algorithm	Engage consult
Broad spectrum agent being used unnecessarily	Develop facility-specific guidanceImplement antibiotic time-out	pharmacists in antibiotic order
Bug-drug mismatches	Antibiogram use for empiric treatment	provide feedba prescribers who
Continuation of empiric antibiotics even after infection ruled out	Implement antibiotic time-out	improvement opportunities a
Inappropriate length of therapy	Develop facility-specific guidanceImplement antibiotic time-out	Build partnersh whenever poss
Unnecessary antibiotics being started by outside providers	 Implement mandatory review of necessity by medical directors for all outside antibiotic orders Antibiotic time-out 	local antibiotic stewardship ex their input on t interventions a
Unnecessary antibiotics being started by specific providers	 Consider providing specific feedback to the providers 	specific protoco

nt nursing cribers ervention

ltant reviewing ers and ack to nen are found

hip, sible, with xperts for the and facility cols

Report the Data to Providers and Staff

What we have achieved so far?


2018 Antimicrobial Stewardship Program Report

Purpose

The purpose of this brief report is to summarize [Facility Name] Antimicrobial Stewardship Program (ASP) accomplishments in 2018 and outline ASP goals for 2019.

Summary of Antimicrobial Stewardship Program Accomplishments in 2018

- Implemented the use of SBAR (standard staff-provider communication tools) for suspected urinary tract, respiratory tract and skin/soft-tissue infections
- Compliance with the use of SBAR for suspected urinary tract infection reached 85-90%
- Provided mandatory annual antimicrobial stewardship education to [number] facility staff
- Reduced antibiotic starts by 34% from 7.17 starts/1000 resident-days in 2017 to 4.73 starts/1000 resident-days in 2018
- Decreased antibiotic days of therapy by 41% from 88.52 days of therapy/1000 resident-days in 2017 to 51.99 days of therapy/1000 resident-days in 2018
- No facility-onset Clostridioides difficile infection (CDI) was identified
- Reviewed antibiotic prescribing for respiratory tract infections (50% orders meeting criteria)



Antimicrobial Stewardship Program Goals for 2019

- Increase compliance to SBAR usage for suspected urinary tract infection to 95%
- Further reduce antibiotic starts and days of therapy by 20%
- Implement SBAR for respiratory tract infections

Concluding Remarks

The Antimicrobial Stewardship Program successes accomplished in 2018 are due to the diligent work of facility staff and support of facility providers in an effort to continue to improve the quality of care for residents at [The ASP team hopes that staff and providers continues these efforts in 2019.

Where we can improve further?

How are we going to achieve it?

Antibiotic Stewardship: A Cycle of Reassessments and Readjustments

- Develop plans to address barriers
- Report/re-educate providers
- Execute mitigation plans

4 Act

1 Plan

- Review data
- Identify opportunities
- Develop action plan
- Inform/report providers

Study

Do

- Implement Action
- Educate providers
- Track antibiotic use
- Track process measures

Analyze data

Study outcomes

Identify implementation barriers

https://asap.nebraskamed.com



ABOUT US ACUTE CARE LONG-TERM CARE ADDITIONAL RESOURCES (



SERIOUS MEDICINE, EXTRAORDINARY CARE,"





Good Life. Great Mission.

DEPT. OF HEALTH AND HUMAN SERVICES

PROVIDING YOU WITH THE RESOURCES TO PROMOTE APPROPRIATE ANTIBIOTIC USE, IMPROVE PATIENT OUTCOMES AND PREVENT ANTIBIOTIC RESISTANCE

Stewardship: Overcoming Barriers

Key Challenges to Successful Antibiotic Stewardship Programs



Clinician resistance—nurse, physician, nurse practitioner, physician's assistants



Family pressure



Resources and turnover

Challenges related to beliefs and pressure

Belief in urinalysis as the gold standard

Cloudy or smelly urine as symptoms

The need to treat

Frentzel, E., Mangrum, R., Cowans, T., Kilany, M., Mcmaughan, D., Barber, D.,...Guo, J. (2016). Process evaluation of the guide to nursing home antimicrobial stewardship. *Open Forum Infectious Diseases, 3 (1,* suppl 1), 1890. https://doi.org/10.1093/ofid/ofw172.1438

Is a positive urinalysis really an indicator?



Nearly half of residents have bacteria in urine¹



Vague symptoms (falling) and a urinalysis leads to an antibiotic

Likelihood of clean catch low; 14% clean²

¹AMDA and Consumer Reports. 2014. Tests & Treatments for Urinary Tract Infections in Older People. Developed for ABIM Foundation's Choosing Wisely. Accessed from: http://www.choosingwisely.org/patient-resources/urinary-tract-infections-in-older-people/

²Juthani-Mehta M, Quagliarello V, Perrelli E, Towle V, Van Ness PH, Tinetti M. Clinical features to identify urinary tract infection in nursing home residents: a cohort study. *J Am Geriatr Soc.* 2009;57(6):963-70.

Cloudy or smelly urine



Dr. Google says so^{1,2}



Cloudy = dehydration³, infections, kidney problems, some chronic diseases.



Smelly = dehydration³, specific foods, other <u>disorders</u>, infections



None of the current guidelines use them

Loeb and SHEA/CDC (aka Stone or revised McGeer)

¹WebMD. (date unknown). Urinary Tract Infections (UTIs). Accessed from: https://www.webmd.com/women/guide/your-guide-urinary-tract-infections#1-3

²Mayo Clinic. Urinary tract infection (UTI). Accessed from: https://www.mayoclinic.org/diseases-conditions/urinary-tract-infection/symptoms-causes/syc-20353447

3Paulis, Simone & H.J. Everink, Irma & Halfens, Ruud & Dr. Lohrmann, Christa & Schols, Jos M.G.A.. (2018). Prevalence and Risk Factors of Dehydration Among Nursing Home Residents: A Systematic Review. Journal of the American Medical Directors Association. 19. 10.1016/j.jamda.2018.05.009.

The need to treat



Pressures from family and other clinicians to treat



Concerns about state surveyors—nursing home pressure to "treat"



Antibiotics seen as key

Addressing Challenges

Education and re-education

 Educate nurses and prescribing clinicians about true symptoms, risks of antibiotics, treatment alternatives to antibiotics

Institute supporting policies and procedures

- Improve communication
- Support for when state comes in

Education and Policy Support

Education: AHRQ Nursing Home Guide, Quality Innovation Networks Quality Improvement Organization, state health departments, CDC

Policy: Society's Antibiotic Stewardship Policy's Appendix 2 (sample policy), Minnesota Department of Health

Orders were provided by clinician through Phone	Fax In	Person 0	ther
□ Chest X-Ray			
□ For cough, consider using a cough suppressant Dose _	Rout	e Dura	tion
☐ For cough, consider using an inhaler/nebulizer ☐ Dose _	Dura	tion	
☐ Acetaminophen mg. Route Duration			
☐ Raise upper body (use multiple pillows) to sleep/rest			
☐ Encourage ounces of fluid by mouth or G-Tube for	or	hours	
Record fluid intake			
☐ Encourage salt water gargles			
☐ Assess vital signs, including temp, every hours	for	_ hours	
□ Notify Physician/NP/PA if symptoms worsen or if unreso	lved in	hours	
□ Initiate intravenous fluid hydration and/or □ initiate hype	odermoclys	sis.	
☐ Initiate the following antibiotic(s)			
Antibiotic 1	Dose	Route _	Duration
Antibiotic 2	Dose	Route _	Duration
☐ No ☐ Yes Pharmacist to adjust for renal function			

.

Family Pressure

- Family member's beliefs in knowledge about resident
- Pressure to treat

"Family members do often ask for antibiotics and that some doctors are quick to prescribe or "cave in" to pressure from family members."¹

¹American Institutes for Research, Texas A & M Health Science Center, TMF Health Quality Institute, University of Wisconsin, University of Pittsburgh, Trivedi Consultants, David Mehr, M.D. Pilot Test Report. 2015. Report funded under contract no. HHSA HHSA290201000018I, Task Order 2 from the Agency for Healthcare Research and Quality (AHRQ).

Addressing Family Pressure

Educate and agree on antibiotic stewardship when residents move in

• CDC, AHRQ

Educate nurses and aides in engaging with family members

 AHRQ Nursing Home Antimicrobial Stewardship Guide Talking Points for Residents and Family Members

Sample: Prepare Families

Here at [FACILITY NAME], we take antibiotic use very seriously, so we are pleased to let you know that we have an antibiotic stewardship policy and program. Antibiotic stewardship is the practice of improving antibiotic use.

[FACILITY NAME] is taking action to make sure that our residents get the best care. Our antibiotic stewardship program goals include:

- making sure residents get antibiotics only when necessary—for bacterial infections, and
- making sure residents get the right antibiotic, at the right time, for the right length of time.

Sample Talking Points

What are the risks—or harms—of antibiotics?

- Antibiotics are important for treating you when you definitely have an infection, but unneeded antibiotics can do more harm than good
- Before taking an antibiotic, it is important to understand how antibiotics could harm or hurt you. There are five potential health problems that occur as a result of taking an antibiotic.
 - Allergic reactions, like a rash or swelling.
 - Side effects, such as a stomach upset.
 - Drug interactions.
 - An infection called Clostridium difficile or C. diff.
 - Antibiotic resistance.

Challenges: Resources and turnover

Lack of money and staff

- Urge leadership to focus more infection preventionist time on antibiotic stewardship
- Make antibiotic stewardship a focus of monthly meetings
- Use free resources, obtain support from QIN-QIOs

Turnover/agency staff

- Institute processes everyone follows
 - Communication tools
 - Suspected UTI SBAR
- Constant education

